News articles about Dermira (NASDAQ:DERM) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dermira earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.6374902784712 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Dermira (DERM) opened at 27.01 on Friday. The firm’s 50-day moving average price is $25.26 and its 200 day moving average price is $28.71. The firm’s market cap is $1.12 billion. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75.

Dermira (NASDAQ:DERM) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.04). Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.00 million. On average, equities research analysts forecast that Dermira will post ($4.20) EPS for the current year.

DERM has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $45.00 price target on shares of Dermira in a research report on Tuesday, September 26th. Zacks Investment Research lowered Dermira from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Mizuho reaffirmed a “buy” rating and set a $43.00 price target (up previously from $40.00) on shares of Dermira in a research report on Thursday, September 7th. BidaskClub lowered Dermira from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Tuesday, July 18th. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Dermira currently has an average rating of “Hold” and an average price target of $44.40.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Dermira (DERM) Stock Price” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/10/06/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-dermira-derm-stock-price.html.

In related news, Director Fred B. Craves purchased 30,000 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The shares were acquired at an average price of $23.03 per share, with a total value of $690,900.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Thomas G. Wiggans sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,800 shares of company stock worth $319,751. 13.30% of the stock is currently owned by company insiders.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.